

Caplyta costs up to $1,800/month without insurance. Learn how to save with coupons, the manufacturer savings card, patient assistance, and more.
Caplyta (Lumateperone) is an effective medication for schizophrenia, bipolar depression, and major depressive disorder — but its price tag can be a shock. Without insurance, Caplyta costs between $1,650 and $1,800 per month for a 30-day supply.
The good news is that there are real ways to reduce what you pay. This guide covers every savings option available in 2026, from manufacturer programs to discount cards and patient assistance.
Here's what you can expect to pay at the pharmacy counter without any insurance or discounts:
Unlike many medications, Caplyta costs roughly the same regardless of the dose strength. And because there is no generic version of Caplyta available in 2026, there's no lower-cost equivalent you can switch to.
That makes it especially important to take advantage of every savings opportunity available.
The manufacturer offers a Caplyta Savings Card that can dramatically reduce your out-of-pocket cost:
Who qualifies:
Who does NOT qualify:
To sign up, visit caplyta.com/cost-savings or ask your doctor or pharmacist about the Caplyta withMe program.
If you don't have insurance — or your insurance doesn't cover Caplyta — prescription discount cards can help, though the savings are more modest for brand-name drugs:
These cards are free to use and don't require insurance. They won't bring the price down to an affordable level for most patients on their own, but they can save you $50-$150 compared to the full retail price.
You can compare prices across cards and pharmacies on each provider's website. Look for the best price at pharmacies near you.
If you're uninsured or underinsured and can't afford Caplyta, the Intra-Cellular Therapies Patient Assistance Program (now through Johnson & Johnson) may provide Caplyta at no cost.
Eligibility typically requires:
To apply, visit intracellulartherapies.com/patient-assistance or ask your doctor's office to submit an application on your behalf.
Additional assistance resources:
If your plan covers Caplyta but places it on a high tier (Tier 4 or Tier 5), you may still face a high copay. Ask your doctor to submit a prior authorization or a formulary exception request to get Caplyta covered at a lower tier.
Some insurance plans offer mail-order pharmacy discounts, especially for 90-day supplies. This can reduce your per-fill cost and ensure consistent access to Caplyta without pharmacy stock issues.
The Caplyta withMe program sometimes offers a free first-fill voucher to patients starting Caplyta for the first time. Ask your prescriber about this option.
Some states offer their own pharmaceutical assistance programs (SPAPs) for residents who don't qualify for Medicaid but need help with drug costs. Check with your state's department of health or insurance.
If Caplyta remains unaffordable, ask your doctor about alternatives to Caplyta. Generic options like Lurasidone (around $30-$50/month) or Quetiapine (around $10-$30/month) may be effective alternatives depending on your condition.
Caplyta is an expensive medication, but you don't have to pay full price. If you have commercial insurance, the manufacturer savings card can bring your cost down to as little as $15. If you're uninsured, the patient assistance program may cover the full cost. And discount cards can help everyone save at least a little at the pharmacy counter.
Start by checking your options at caplyta.com, and use Medfinder to find a pharmacy near you that has Caplyta in stock. For more about availability, see our Caplyta shortage update for 2026.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.